KEGG   DRUG: Fluticasone furoate and vilanterol trifenatateHelp
Entry
D10501            Mixture   Drug                                   

Name
Fluticasone furoate and vilanterol trifenatate;
Breo ellipta (TN);
Relvar ellipita (TN)
Product
Component
Fluticasone furoate [DR:D06315], (Vilanterol trifenatate [DR:D09697] | Vilanterol [DR:D09696])
Class
Metabolizing enzyme substrate
 DG02913  CYP3A4 substrate
Remark
Therapeutic category: 2290
ATC code: R03AK10
Product: D10501<JP/US>
Efficacy
Antiasthmatic
  Disease
Chronic obstructive pulmonary disease [DS:H01714]
Asthma [DS:H00079]
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03A ADRENERGICS, INHALANTS
    R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
     R03AK10 Vilanterol and fluticasone furoate
      D10501  Fluticasone furoate and vilanterol trifenatate <JP/US>
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Respiratory Tract Agents, Other
   Fluticasone furoate/Vilanterol trifenatate
    D10501  Fluticasone furoate and vilanterol trifenatate
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D10501  Fluticasone furoate and vilanterol trifenatate
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10501
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10501
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10501
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10501
BRITE hierarchy
Other DBs
PubChem: 172232594
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system